In vivo visualization of tau deposits in corticobasal syndrome by ¹⁸ F-THK5351 PET

Abstract

<h3>Objective:</h3> To determine whether ¹⁸F-THK5351 PET can be used to visualize tau deposits in brain lesions in live patients with corticobasal syndrome (CBS). <h3>Methods:</h3> We evaluated the in vitro binding of ³H-THK5351 in postmortem brain tissues from a patient with corticobasal degeneration (CBD). In clinical PET studies, ¹⁸F-THK5351 retention in 5 patients with CBS was compared to that in 8 age-matched normal controls and 8 patients with Alzheimer disease (AD). <h3>Results:</h3> ³H-THK5351 was able to bind to tau deposits in the postmortem brain with CBD. In clinical PET studies, the 5 patients with CBS showed significantly higher ¹⁸F-THK5351 retention in the frontal, parietal, and globus pallidus than the 8 age-matched normal controls and patients with AD. Higher ¹⁸F-THK5351 retention was observed contralaterally to the side associated with greater cortical dysfunction and parkinsonism. <h3>Conclusions:</h3> ¹⁸F-THK5351 PET demonstrated high tracer signal in sites susceptible to tau deposition in patients with CBS. ¹⁸F-THK5351 should be considered as a promising candidate radiotracer for the in vivo imaging of tau deposits in CBS.